{"disease":{"id":"nsclc-stage-iv","name":"nsclc stage iv"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06788366","title":"AI-HOPE Lung Cancer: Building a Predictive Tool for Metastatic Lung Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"IRCCS San Raffaele","has_results":false},{"nct_id":"NCT04633564","title":"MYL-1402O Compared With Avastin®, in Patients With Stage IV nsNSCLC","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":671,"lead_sponsor_name":"Mylan Pharmaceuticals Inc","has_results":true},{"nct_id":"NCT05701787","title":"Molecular Landscape Analysis and Clinical Implications for NSCLC Patients With Rare Mutations","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Shanghai Chest Hospital","has_results":false},{"nct_id":"NCT07150598","title":"Immune-Marker Platform for Patients With Advanced Lung Cancer","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Technische Universität Dresden","has_results":false},{"nct_id":"NCT06947694","title":"A Study on Exploring the Abscopal Effect Induced by Different Radioimmunotherapy Combination Patterns in the Treatment of Non-Small Cell Lung Cancer With Multiple Metastases","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":427,"lead_sponsor_name":"Xinqiao Hospital of Chongqing","has_results":false},{"nct_id":"NCT06953843","title":"Study on the Optimal Combination Pattern of the Combined Treatment of Radiotherapy and Immunotherapy for the Abscopal Effect in Non-Small Cell Lung Cancer (NSCLC) With Multiple Metastases","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":366,"lead_sponsor_name":"Xinqiao Hospital of Chongqing","has_results":false},{"nct_id":"NCT02864992","title":"Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":337,"lead_sponsor_name":"EMD Serono Research & Development Institute, Inc.","has_results":true},{"nct_id":"NCT04492969","title":"Prospective Observation of Failure Patterns in NSCLC Treated With ICIs","phase":"","overall_status":"UNKNOWN","enrollment_count":320,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT05014815","title":"Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":272,"lead_sponsor_name":"BeiGene","has_results":true},{"nct_id":"NCT05652868","title":"Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":227,"lead_sponsor_name":"Mythic Therapeutics","has_results":false},{"nct_id":"NCT04306094","title":"Factors Determining the Prognosis in NSCLC Stage IV","phase":"","overall_status":"UNKNOWN","enrollment_count":217,"lead_sponsor_name":"Instituto do Cancer do Estado de São Paulo","has_results":false},{"nct_id":"NCT04102982","title":"Microwave Ablation in Combination With Camrelizumab Versus Camrelizumab in Metastatic Non-small-cell Lung Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Shandong Provincial Hospital","has_results":false},{"nct_id":"NCT05132218","title":"Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":180,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT07279402","title":"TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50%","phase":"","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Antalya Training and Research Hospital","has_results":false},{"nct_id":"NCT04042558","title":"A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Centre Francois Baclesse","has_results":false},{"nct_id":"NCT06313541","title":"Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunotherapy","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":146,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT05344209","title":"Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":138,"lead_sponsor_name":"Vestre Viken Hospital Trust","has_results":false},{"nct_id":"NCT06114108","title":"Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV NSCL Cancer Patients","phase":"NA","overall_status":"RECRUITING","enrollment_count":128,"lead_sponsor_name":"Swiss Cancer Institute","has_results":false},{"nct_id":"NCT03341494","title":"EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":128,"lead_sponsor_name":"Fujian Cancer Hospital","has_results":false},{"nct_id":"NCT04027647","title":"Phase 2 Study of Dacomitinib in NSCLC","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":118,"lead_sponsor_name":"National Cancer Centre, Singapore","has_results":false},{"nct_id":"NCT04745715","title":"Genomic Study in Non-small Cell Lung Cancer Brain Metastasis","phase":"","overall_status":"COMPLETED","enrollment_count":110,"lead_sponsor_name":"National Cheng-Kung University Hospital","has_results":false},{"nct_id":"NCT06234579","title":"Longitudinal Assessment of Genomic Alterations and Clonal Evolution in ALK-positive NSCLC (Galileo Project)","phase":"","overall_status":"RECRUITING","enrollment_count":108,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT04136535","title":"Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":105,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT05597800","title":"Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":105,"lead_sponsor_name":"Universita di Verona","has_results":false},{"nct_id":"NCT06374160","title":"Exercise in Patients With Advanced Non-small Cell Lung Cancer","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":104,"lead_sponsor_name":"University Hospital, Essen","has_results":false},{"nct_id":"NCT04116918","title":"Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Baodong Qin","has_results":false},{"nct_id":"NCT05311709","title":"Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Vestre Viken Hospital Trust","has_results":false},{"nct_id":"NCT03454685","title":"The Role of Microbiota on the Development of Lung Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Xiaorong Dong","has_results":false},{"nct_id":"NCT03184571","title":"Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":99,"lead_sponsor_name":"BerGenBio ASA","has_results":true},{"nct_id":"NCT06339554","title":"Alectinib-induced Endocrine Toxicity","phase":"","overall_status":"COMPLETED","enrollment_count":98,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT05543330","title":"A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":96,"lead_sponsor_name":"Wuhan YZY Biopharma Co., Ltd.","has_results":false},{"nct_id":"NCT03705403","title":"IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":88,"lead_sponsor_name":"Maastricht University Medical Center","has_results":false},{"nct_id":"NCT04768491","title":"Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC","phase":"","overall_status":"UNKNOWN","enrollment_count":82,"lead_sponsor_name":"Peking Union Medical College","has_results":false},{"nct_id":"NCT03564197","title":"18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC","phase":"NA","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"The Netherlands Cancer Institute","has_results":false},{"nct_id":"NCT06532149","title":"ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT03363139","title":"T790M Mutation Testing in Blood by Different Methodologies","phase":"","overall_status":"COMPLETED","enrollment_count":72,"lead_sponsor_name":"Spanish Lung Cancer Group","has_results":false},{"nct_id":"NCT05157776","title":"A Phase III Trial of Neoadjuvant Sintilimab and Chemotherapy for NSCLC Harboring No Driver Mutations","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":72,"lead_sponsor_name":"Tongji University","has_results":false},{"nct_id":"NCT05657873","title":"A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":68,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT04291092","title":"Camrelizumab Combined With Local Treatment in NSCLC Patients With BM","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":63,"lead_sponsor_name":"Zhejiang Cancer Hospital","has_results":false},{"nct_id":"NCT04106180","title":"SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":63,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT04764214","title":"SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT03960034","title":"Cachexia in NSCLC Patients: Diagnosis, Characterization, Prognosis, Functional and Skeletal Muscle Implications","phase":"","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Instituto do Cancer do Estado de São Paulo","has_results":false},{"nct_id":"NCT04767009","title":"SBRT for Oligo-residual NSCLC After Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":59,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT05274451","title":"A Study to Investigate LYL797 in Adults With Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":57,"lead_sponsor_name":"Lyell Immunopharma, Inc.","has_results":false},{"nct_id":"NCT05816499","title":"Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC)","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Shanghai Chest Hospital","has_results":false},{"nct_id":"NCT03620669","title":"1st Line Durvalumab in PS 2 NSCLC Patients","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":48,"lead_sponsor_name":"Swiss Cancer Institute","has_results":false},{"nct_id":"NCT04636775","title":"Microbiome in Immunotherapy naïve NSCLC Patients Receiving PD-1/L1 Blockade (MIP_NSCLC)","phase":"","overall_status":"UNKNOWN","enrollment_count":46,"lead_sponsor_name":"Jun Zhang, MD, PhD","has_results":false},{"nct_id":"NCT05303493","title":"Camu-Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-small Cell Lung Cancer and Melanoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"Centre hospitalier de l'Université de Montréal (CHUM)","has_results":false},{"nct_id":"NCT07339839","title":"Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":42,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT04521075","title":"A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":42,"lead_sponsor_name":"Ella Therapeutics Ltd","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}